US FDA approves Pfizer's next-generation pneumococcal vaccine
The U.S. Food and Drug Administration has approved Pfizer Inc's next-generation vaccine to prevent pneumococcal disease in children aged six weeks to 17 years, the company said late on Thursday.... | April 28, 2023